✦ LIBER ✦

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

✍ Scribed by Meletios A. Dimopoulos; Maria-Victoria Mateos; Paul G. Richardson; Rudolf Schlag; Nuriet K. Khuageva; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Antonio Palumbo; Ka Lung Wu; Dixie-Lee Esseltine; Kevin Liu; William Deraedt; Andrew Cakana; Helgi Van De Velde; Jesús F. San Miguel

Book ID: 114794856
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 129 KB
Volume: 86
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2010.01533.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mechanisms of peripheral neuropathy asso

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

✍ Annemiek Broyl; Sophie L Corthals; Joost LM Jongen; Bronno van der Holt; Rowan K 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 125 KB

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB